First-in-Class Composite Angiotensin Receptor–Neprilysin Inhibitors (ARNI) in Practice

    loading  Checking for direct PDF access through Ovid

Abstract

Sacubitril/valsartan, a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. It is recommended in heart failure with reduced ejection fraction (HFrEF) as a result of the PARADIGM-HF trial.1 This review discusses the rationale for neprilysin inhibition, data supporting efficacy, and practical tips for patient selection and utilization.

Related Topics

    loading  Loading Related Articles